Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study.
The authors assessed the safety and efficacy of creatine monohydrate (Cr) in various types of muscular dystrophies in a double-blind, crossover trial. Thirty-six patients (12 patients with facioscapulohumeral dystrophy, 10 patients with Becker dystrophy, 8 patients with Duchenne dystrophy, and 6 patients with sarcoglycan-deficient limb girdle muscular dystrophy) were randomized to receive Cr or placebo for 8 weeks. There was mild but significant improvement in muscle strength and daily-life activities by Medical Research Council scales and the Neuromuscular Symptom Score. Cr was well tolerated throughout the study period.
Walter
M C
MC
Friedrich-Baur-Institute, Ludwig-Maximilians-University of Munich, Germany. Maggie.Walter@lrz.uni-muenchen.de
Lochmüller
H
H
Reilich
P
P
Klopstock
T
T
Huber
R
R
Hartard
M
M
Hennig
M
M
Pongratz
D
D
Müller-Felber
W
W
D000203:Activities of Daily Living / Q000145:classification; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003401:Creatine / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007537:Isometric Contraction / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009136:Muscular Dystrophies / Q000188:drug therapy* / Q000235:genetics; D009460:Neurologic Examination / Q000187:drug effects; D016896:Treatment Outcome; D014797:Vital Capacity / Q000187:drug effects
D003401:Creatine